Apellis Pharmaceuticals ( (APLS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Apellis Pharmaceuticals’ stock price movement has been driven by its strong financial performance, reporting $611 million in U.S. net product revenues for SYFOVRE and $98 million for EMPAVELI. Despite changes in the executive team, the company’s financial stability is evident with $410 million in year-end cash and plans for future drug developments. RBC Capital raised its price target due to these robust financials and growth prospects. However, Goldman Sachs downgraded the stock due to concerns over potential market challenges and uncertainties related to upcoming trials and regulatory approvals.
More about Apellis Pharmaceuticals
YTD Price Performance: -17.25%
Average Trading Volume: 3,137,521
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.41B
For further insights into APLS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.